TiGenix Merges with Cellerix in $79.7M All-Share Deal

LONDON – TiGenix NV is merging with fellow cell therapy specialist Cellerix SA in an all-share deal valuing Cellerix at €58 million (US$79.7 million), creating a clear leader in the European regenerative medicine field, with two marketed products and a number of allogeneic adult stem cell therapies in clinical development.